Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 1:15 AM
Ignite Modification Date:
2025-12-25 @ 1:15 AM
NCT ID:
NCT01902693
Eligibility Criteria:
Inclusion Criteria:
* Aged ≥ 18 years and able to give written informed consent
* Be aware of their HIV status and the diagnosis of malignancy
* Have a plasma viral load of \< 50 HIV-1 RNA copies/ml (on suppressive HAART) at enrolment
* Be designated to receive cytotoxic chemotherapy including one or more of the following agents: R-CHOP, ABVD, Liposomal doxorubicin (Caelyx) or liposomal daunorubicin (Daunoxome) or Paclitaxel
Exclusion Criteria:
* Patients not receiving HAART
* A detectable (\>50 HIV-1 RNA copies/ml) HIV plasma viral load at screening
* Opportunistic infections
* Unable or unwilling to give informed consent
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT01902693
Study Brief:
Protocol Section:
NCT01902693